BIIB Biogen Inc

$BIIB the potential of this nearly 12 year down trend break could be huge after reclaiming the false base breakdown.

$BIIB $243.49 52 week high, was worried it would reverse the moment I got involved but trend intact for now

$BIIB This stock performance is goofy AF. I'm getting out while I've still got a profit.

$BIIB is still paying for Apellis in its cost of sales, and the filing puts a number on it. The inventory fair value step-up from the deal ran 100.0 million dollars through cost of sales in the third quarter alone, and 169.7 million dollars over nine months. Total step-up was 541.5 million dollars on 681.0 million dollars of acquired inventory for SYFOVRE and EMPAVELI, and the rest keeps amortizing as that inventory sells, on a schedule through the end of 2029.

$BIIB seeing increased options activity today. At last look, over 7.5k options have changed hands, volume that's more than triple the average intraday amount The weekly 11/6 250-strike put is the most popular, followed closely by the December 250 put BIIB has moved lower today despite a beat-and-raise Year to date, the drug stock is up 45.4%

$BIIB reported earnings before the open today. EPS beat estimates: $2.62 vs. $1.98 expected, according to Stock Meadow. What do you think?

$BIIB Can Biogen's 11% revenue growth carry earnings after quarterly non-GAAP EPS fell 46%? 🏢 Biogen, the Cambridge, Mass. biotech behind Spinraza and Leqembi, grew Q3 2026 revenue 11% to $2.804B with its first full quarter of Apellis products, against a market value of about $37.31B at $252.73 at 16:00 ET on October 27, 2026 📉 Quarterly non-GAAP EPS fell 46% to $2.62 from $4.81 a year earlier, mostly on a $284M acquired IPR&D charge mainly for buying RayThera, and GAAP results swung to a $(0.14) loss per share from a $3.17 profit 🚀 On the other side, the Growth Portfolio rose 49% to $1.26B and full-year non-GAAP EPS guidance rose to $12.20–$13.00, after about $3.20 a share of expected acquired IPR&D charges, while the underlying range is $15.95–$16.75 📅 Next: Top-line Phase 3 TOPAZ-1 and TOPAZ-2 data for litifilimab in lupus (SLE) are expected in the first half of December 2026 Source: SEC 8-K and Q3 release, Oct 28

$BIIB | Biogen Q3 2026 Earnings: - Adj EPS: $2.62 (est $2.06) - Revenue: $2.80B (est $2.64B) - Product Revenue: $2.09B (est $1.94B) - Multiple Sclerosis Revenue: $919M (est $903.6M) - Sees FY Adjusted EPS: $12.20 To $13 (prev $12 To $13; est $12.38)

$BIIB I've had this one a while. ~$20 per share profit. Money would have been better off sitting in $VOO. $BIIB had an big upgrade recently. Their price movement can get pretty wild. I wouldn't be suprised either way on this one.

$BIIB reports earnings tomorrow before the open. I’m bullish heading into the report: BIIB has beaten EPS estimates in 8 of its last 8 reports, according to Stock Meadow. Analysts expect EPS of $1.98. What are you watching for?

$BIIB add 237.96, but I am very late to the trend change here which began after bottoming at $115 a week after Liberation Day.

BIIB Stock: JPMorgan Sees ‘Increasingly Compelling Catalyst Path’ For Biogen, Raises Price Target To $300 $BIIB https://stocktwits.com/news/equity/markets/biogen-biib-stock-jpmorgan-upgrade-300-price-target-pipeline/cZxI75sRBFz

$BIIB got a MASSIVE ATM call order expiring in March! Reclaimed the previous resistance zone as support (with the 50DMA being respected) - looks great to shoot towards $229!

$BIIB Q3 '26 Earnings Results & Recap • Reported GAAP EPS of $2.62 down -45.53% YoY • Reported revenue of $2.8B up 10.63% YoY • Biogen raised FY 2026 reported Non-GAAP diluted EPS guidance to $12.20 to $13.00 from $12.00 to $13.00; full-year revenue is expected to increase by a mid-single digit percentage.

$BIIB JPMorgan upgraded to Overweight from Neutral this morning and lifted the target to 300 from 210 (a December 2027 number, per The Fly). Their case is that Biogen's more than a Leqembi stock: felzartamab's phase 3 in antibody-mediated rejection is the lead catalyst, a market over 2 billion dollars, with litifilimab's two cutaneous lupus phase 3 readouts behind it. About 14x JPMorgan's 2027 EPS. Up around 3% in premarket trading, near its highest since July 2024.

$BIIB b 10/2 just 13 220.39 s just now 10/7 2:28 pm edt 223.70 BAMB! HERE ! I don't have the size of account that Robin or Grandpa has